Sheel Biotech Other Announcement
Sheel Biotech intimated that its Statutory Auditor Shyam Sunder Mangla & Co LLP has changed its name to S S Mangla & Co LLP effective 18 December 2025. No change in the auditor appointment itself.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements with these filters
Sheel Biotech intimated that its Statutory Auditor Shyam Sunder Mangla & Co LLP has changed its name to S S Mangla & Co LLP effective 18 December 2025. No change in the auditor appointment itself.
Sheel Biotech Limited submitted the Monitoring Agency Report for the half-year ended March 31, 2026, detailing the utilization of IPO proceeds as per SEBI regulations.
Sheel Biotech Limited filed its Statement of Investor Complaints for the quarter ended June 30, 2026. The company reported nil pending complaints.
Sheel Biotech Limited submitted its annual Structured Digital Database (SDD) compliance certificate for the financial year ended March 31, 2026. Issued by Gulista & Associates, the certificate confirms the company maintains a non-tamperable database capturing all UPSI events as required by SEBI PIT Regulations.
Sheel Biotech Limited submitted a declaration stating that the requirement to file an Annual Secretarial Compliance Report for FY 2025-26 is not applicable. The company qualifies for this exemption as it is listed on the NSE SME Exchange. This is a routine regulatory update with no material financial impact.
Sheel Biotech Limited promoter Divye Chandak submitted a declaration confirming that the promoter group and persons acting in concert made no new encumbrances on their shares during the financial year ended March 31, 2026. This is a routine annual compliance filing under SEBI SAST Regulations.
Sheel Biotech Limited submitted its quarterly compliance certificate under Regulation 74(5) for the period ended March 31, 2026. The registrar, Skyline Financial Services, confirmed no physical shares were received for dematerialization during the quarter. This is a routine administrative disclosure for regulatory records.
Sheel Biotech Limited informed the National Stock Exchange that Corporate Governance Report filing requirements under Regulation 27(2) are not applicable to the company. As an entity listed on the NSE SME Platform, it claims exemption under Regulation 15(2) of SEBI LODR Regulations for the quarter ended March 31, 2026.